SCHEMBL7127086

SCHEMBL7127086

COc1ccc(Nc2ccc(Nc3nc(C)nc4cc(-c5ccccc5)sc34)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 4/20 0.54
MEN1 O00255 6/20 0.54
KMT2A Q03164 6/20 0.54
MAPT P10636 5/20 0.54
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 3/20 0.54
HTT P42858 3/20 0.54
HPGD P15428 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
CYP1A2 P05177 1/20 0.54
GLA P06280 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
EGFR P00533 4/20 0.49
FGFR1 P11362 1/20 0.49
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7119481 0.83 FLT1 (0.80) FLT1MEN1KMT2AMAPTKDM4E
SCHEMBL7129255 0.77 FLT1 (0.72) FLT1EGFRKDR
SCHEMBL7126443 0.76 EGFR (0.77) FLT1MEN1KMT2AMAPTKDM4E
SCHEMBL7116857 0.76 FLT1 (0.78) FLT1MEN1KMT2AMAPTKDM4E
SCHEMBL3108501 0.75 NPY5R (0.72) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL14530536 0.73 EGFR (0.49) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL7119409 0.71 FLT1 (0.85) FLT1EGFRRAB9ANPC1POLB
SCHEMBL14776841 0.71 FLT1 (0.72) FLT1MEN1KMT2AHTTCYP1A2
SCHEMBL7128206 0.71 EGFR (0.77) FLT1MEN1KMT2AMAPTKDM4E
SCHEMBL7118689 0.70 EGFR (0.94) FLT1MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US claimed
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US disclosed
US-6492383-B1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2002-12-10 US disclosed
EP-1028964-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2000-08-23 EP disclosed
WO-1999024440-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents TYMP, DPYD, HPRT1 FLT1 1043/4885MEN1 888/4885KMT2A 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.